References
- Tanaka K, Watanabe T, Takeuchi A, CKD-JAC Investigators, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227–234.
- Huang CK, Bar C, Thum T. miR-21, mediator, and potential therapeutic target in the cardiorenal syndrome. Front Pharmacol. 2020;11:726.
- Oury C, Servais L, Bouznad N, et al. MicroRNAs in valvular heart diseases: potential role as markers and actors of valvular and cardiac remodeling. IJMS. 2016;17(7):1120.
- Deng J, Zhong Q. Advanced research on the microRNA mechanism in heart failure. Int J Cardiol. 2016;220:61–64.
- Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20(9):1487–1495.
- Latifkar A, Hur YH, Sanchez JC, et al. New insights into extracellular vesicle biogenesis and function. J Cell Sci. 2019;132(13):jcs222406.
- Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
- Zhou Y, Xiong M, Fang L, et al. miR-21-containing microvesicles from injured tubular epithelial cells promote tubular phenotype transition by targeting PTEN protein. Am J Pathol. 2013;183(4):1183–1196.
- Onuigbo MA. RAAS inhibition and cardiorenal syndrome. Curr Hypertens Rev. 2014;10(2):107–111.
- Borges FT, Melo SA, Ozdemir BC, et al. TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 2013;24(3):385–392.
- Hugel B, Martinez MC, Kunzelmann C, et al. Membrane microparticles: two sides of the coin. Physiology. 2005;20:22–27.
- Melak T, Baynes HW. Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review. EJIFCC. 2019;30(2):179–194.
- Yuan J, Chen H, Ge D, et al. Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7. Cell Physiol Biochem. 2017;42(6):2207–2219.
- Gu S, Zhang W, Chen J, et al. EPC-derived microvesicles protect cardiomyocytes from Ang II-induced hypertrophy and apoptosis. PLOS One. 2014;9(1):e85396.
- Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One. 2013;8(2):e58014.
- Chuppa S, Liang M, Liu P, et al. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in cardiorenal syndrome type 4. Kidney Int. 2018;93(2):375–389.
- He Y, Huang C, Li J. miR-21 is a critical therapeutic target for renal fibrosis. Cell Biochem Biophys. 2014;68(3):635–636.
- Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124(5):2136–2146.
- Kakimoto Y, Ito S, Abiru H, et al. Sorbin and SH3 domain-containing protein 2 is released from infarcted heart in the very early phase: proteomic analysis of cardiac tissues from patients. J Am Heart Assoc. 2013;2(6):e000565.
- Cheng H, Kimura K, Peter AK, et al. Loss of enigma homolog protein results in dilated cardiomyopathy. Circ Res. 2010;107(3):348–356.
- Wang Y, Liang Y, Zhao W, et al. Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome. Sci Rep. 2020;10(1):4894.
- Ben-Nun D, Buja LM, Fuentes F. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. Cardiovasc Pathol. 2020;49:107243.